Keywords: مهار کننده PARP; Prostate Cancer; DNA repair; Biomarker; PARP inhibitor; Germline;
مقالات ISI ترجمه شده مهار کننده PARP
مقالات ISI مهار کننده PARP (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده PARP; ARV-825 PubChem CID 92044400; BETd-246 PubChem CID 131698640; dBET1 PubChem CID 91799313; I-BET151 PubChem CID 52912189; I-BET762 PubChem CID 46943432; JQ1 PubChem CID 46907787; MS417 PubChem CID 59190723; OTX015 PubChem CID 9936746; THZ1 PubChem CID 7360
Keywords: مهار کننده PARP; Prostate cancer; Tumor vaccine; Immunotherapy; PARP inhibitor; Checkpoint inhibitor;
Keywords: مهار کننده PARP; 3-MA; 3-methyladenine; Asc; ascorbate; ATM; ataxia telangiectasia mutated; ATP; adenosine triphosphate; BRAF; murine sarcoma viral oncogene homolog B; Cat; catalase; Chk2; checkpoint kinase 2; CQ; chloroquine; Cys-SO3H; cysteine S-sulfate; DHA; dehydroasc
Keywords: مهار کننده PARP; targeted therapy; ovarian cancer; anti-angiogenesis; PARP inhibitor; immunotherapy;
Keywords: مهار کننده PARP; Ovarian cancer; BRCAness; Homologous recombination; Platinum; PARP inhibitor; Alkylating agents; HRness; BRCA mutation;
Keywords: مهار کننده PARP; Cancer stem cells; PARP inhibitor; ABT-888; Quinacrine; APC
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
Keywords: مهار کننده PARP; PARP inhibitor; RNA interference screen; DDB1; XAB2; XRCC1;
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
Keywords: مهار کننده PARP; Pharmacodynamic assay; PARP inhibitor; Chemoradiation; Olaparib (Lynparzaâ¢); RT combination trials;
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Keywords: مهار کننده PARP; Pancreatic cancer; Veliparib; BRCA; Germline; PARP inhibitor; Platinum;
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Keywords: مهار کننده PARP; Ovarian cancer; Phase I; Veliparib; PARP inhibitor; BRCA1/2 mutations;
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer
Keywords: مهار کننده PARP; Ovarian cancer; PARP inhibitor; Rucaparib; HRD; BRCA mutation;
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
Keywords: مهار کننده PARP; Triple negative breast cancers; PARP inhibitor; Histone deacetylase inhibitor; Homologous recombination; BRCA1 mutated cells;
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
Keywords: مهار کننده PARP; Epithelial ovarian cancer; PARP inhibitor; Olaparib; Veliparib; Rucaparib; Niraparib;
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Keywords: مهار کننده PARP; Ovarian cancer; BET inhibitor; PARP inhibitor; Homologous recombination;
Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas
Keywords: مهار کننده PARP; PARP inhibitor; Radiosensitization; Radiotherapy; BRCA1; HGSOC;
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
Keywords: مهار کننده PARP; BRCA reversion; Circulating tumor DNA; ctDNA; Metastatic breast cancer; PARP inhibitor;
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
Keywords: مهار کننده PARP; PARP; poly (ADP-ribose) polymerase; TMZ; temozolomide; BER; base-excision repair; MGMT; O-6-methylguanine-DNA methyltransferase; NHEJ; non-homologous end joining; HR; homologous recombination; 3-AB; 3-aminobenzamide; MTIC; 5-(3-methyltriazen-1-yl)imidazol
A yeast growth assay to characterize plant poly(ADP-ribose) polymerase (PARP) proteins and inhibitors
Keywords: مهار کننده PARP; Arabidopsis thaliana; Growth inhibition; PARP inhibitor; Poly(ADP-ribose) polymerase; Yeast assay;
Cancer de la prostate et gènes de réparation de l'ADN
Keywords: مهار کننده PARP; BRCA2; BRCA1; Dépistage ciblé; Inhibiteur de PARP; Sur-incidence; BRCA1; BRCA2; Specific screening; PARP inhibitor; Over-incidence;
Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma
Keywords: مهار کننده PARP; PARP inhibitor; PET; Imaging; Olaparib; Mesothelioma;
Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma
Keywords: مهار کننده PARP; PARP inhibitor; Treatment; Maintenance; Ovarian cancer;
NF90 regulates PARP1 mRNA stability in hepatocellular carcinoma
Keywords: مهار کننده PARP; NF90; PARP1; mRNA stability; Hepatocellular carcinoma; PARP inhibitor;
Original ArticleCRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation
Keywords: مهار کننده PARP; Cas9; ERBB2; Breast cancer; PARP inhibitor; Trastuzumab; Therapeutic;
Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells
Keywords: مهار کننده PARP; Sigma-2 receptor; PARP inhibitor; Breast cancer; Therapeutics; Synergy; Synthetic lethal;
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Keywords: مهار کننده PARP; Rucaparib; PARP inhibitor; Ovarian carcinoma; Somatic, germline BRCA mutation;
Original ArticlePoly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells
Keywords: مهار کننده PARP; Acute lymphoblastic leukemia; TCF3-HLF; Homologous recombination repair; PARP inhibitor;
Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease
Keywords: مهار کننده PARP; Non-alcoholic fatty liver disease; Poly ADP-ribosylation; Sirtuin; PARP inhibitor; PARylation; NAD;
EJC Biennial ReportGenomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
Keywords: مهار کننده PARP; Ovarian cancer; Double-strand breaks; DNA repair; Homologous recombination; Alternative end joining; Non-homologous end joining; PARP inhibitor; Whole-genome sequencing; Mutational signatures; Rearrangement signatures;
Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy
Keywords: مهار کننده PARP; β-thujaplicin; Radiosensitizer; Homologous recombination; DNA repair; PARP inhibitor;
Relevance of DNA damage repair in the management of prostate cancer
Keywords: مهار کننده PARP; Prostate cancer; DNA-repair gene defects; BRCA mutation; PARP inhibitor; Immunotherapy;
The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids
Keywords: مهار کننده PARP; Glioblastoma; PARP inhibitor; Topoisomerase I inhibitor; Topotecan; Radiosensitivity;
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer
Keywords: مهار کننده PARP; Veliparib; PARP inhibitor; NSCLC; smoking history;
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer
Keywords: مهار کننده PARP; High-grade serous ovarian cancer; PARP inhibitor; BRCAness; Homologous recombination
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer
Keywords: مهار کننده PARP; Zj-6413; PARP inhibitor; Breast cancer; BRCA deficient; DNA damage repair
PARP inhibitor combination therapy
Keywords: مهار کننده PARP; PARP inhibitor; Drug combinations; BRCA1; BRCA2;
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG O
Keywords: مهار کننده PARP; Veliparib; Ovarian cancer; PARP inhibitor; Toxicity; Phase II trial; BRCA1, BRCA2 mutation
Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells
Keywords: مهار کننده PARP; Curcumin; PARP inhibitor; Breast cancer cells; Homologous-recombination repair; Chemotherapy;
Towards small molecule inhibitors of mono-ADP-ribosyltransferases
Keywords: مهار کننده PARP; Mono-ADP-ribosyltransferase; mART; Poly(ADP-ribose) polymerase; Diphtheria toxin-like ADP-ribosyltransferase; ARTD inhibitor; PARP inhibitor;
DNA polymerase β-dependent cell survival independent of XRCC1 expression
Keywords: مهار کننده PARP; DNA polymerase β; XRCC1; Methyl methanesulfonate; PARP inhibitor; Camptothecin
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
Keywords: مهار کننده PARP; Radiosensitization; Targeted agent; PARP inhibitor; Optimal biological dose; Olaparib (Lynparzaâ¢);
Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer
Keywords: مهار کننده PARP; Imidazo[4,5-c]pyridine-7-carboxamide; PARP inhibitor; Antitumor
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity
Keywords: مهار کننده PARP; PARP inhibitor; Fanconi anemia; Warsaw breakage syndrome; Sister chromatid cohesion; FANCM; DDX11
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion
Keywords: مهار کننده PARP; Ovarian carcinogenesis; Oxidative stress; Nrf2 (NFE2L2); BRCA1; PARP inhibitor; ARE; antioxidant response element; ATF; artificial transcription factor; BER; base excision repair; CRISPR/Cas9; clustered regularly interspaced short palindromic repeats asso
A whole genome RNAi screen identifies replication stress response genes
Keywords: مهار کننده PARP; Replication stress; ATR; Checkpoint; RNAi screen; DNA damage; Hydroxyurea; Gemcitabine; Camptothecin; PARP inhibitor;
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma
Keywords: مهار کننده PARP; AUC; area under the plasma concentration-time curve; LLOQ; lower limit of quantification; PARP; poly(ADP-ribose) polymerase; SRM; selected reaction monitoring; T1/2; elimination half-life; QC; quality control; Rucaparib; PARP inhibitor; LC-MS/MS; Plasma
Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways
Keywords: مهار کننده PARP; Fanconi anemia; Nucleotide excision repair; Crosslink repair; BRCA; PARP inhibitor;
Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-Resistant prostate cancer cell line, PC3
Keywords: مهار کننده PARP; INPP4B; Combined; PARP inhibitor; Castration therapy-resistant prostate cancer; PC3; PTEN;
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
Keywords: مهار کننده PARP; Ovarian cancer; PARP inhibitor; Homologous recombination deficiency; Rad51
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells
Keywords: مهار کننده PARP; Linifanib (ABT-869); Veliparib (ABT-888); PARP inhibitor; DNA damage; Homologous recombination repair; Apoptosis; Head and Neck Squamous Cell Carcinoma;